Orano Med

🎉 Recap on our participation at ESMO 2024! We were thrilled to be present at ESMO - European Society for Medical Oncology 2024, an essential event for oncology professionals. This gathering provided a great platform to showcase our latest advancements and strengthen collaborations with experts worldwide. 🔬 This year, we highlighted our innovative work in lead-212 based radioligand therapies, which opens up new possibilities for patients with unmet medical needs. We were also thrilled to announce, alongside Radiomedix, Inc. , that we signed a licensing agreement with Sanofi for AlphaMedix just a few days prior to the event. This significant milestone underscores our commitment to developing cutting-edge therapeutic solutions. 💊 Thank you to everyone we connected with at the event and to #ESMO for organizing this international gathering. 📽️ Check out the recap of our participation at ESMO in this video ⬇️ Julien Dodet #ESMO2024 #Oncology #MedicalInnovation #RLT #TargetedTherapies #Lead212 #OranoMed #AlphaMedix #CancerResearch

Thrilled to share my recent interview with Brad Loncar where we discussed Orano Med’s pioneering work in #RadioLigandTherapy. A big thank you to BiotechTV for the opportunity to share our vision and the impactful work we are doing at Orano Med 🙏. #Biotech #CancerResearch #RLT #Healthcare #DARPin #Oranomed #TargetedAlphaTherapy

🚀 Licencing agreement for AlphaMedix! 🚀    We are thrilled to announce the signing of an exclusive licensing agreement with Sanofi for the commercialization of our most advanced treatment, AlphaMedix™, developed in partnership with Radiomedix, Inc. 🎉 This agreement marks a significant milestone in our development strategy and opens up promising new opportunities for #OranoMed.    🤝 With the potential commercialization of AlphaMedix™ in the coming years, we have strategically chosen to entrust its global commercialization to a leading pharmaceutical company. Orano Med will ensure the worldwide production of AlphaMedix™ through our rapidly expanding industrial platform, while #Sanofi will manage its global commercialization. With our large-scale production capacities and pre-established raw material stocks, combined with Sanofi’s extensive commercial reach, we are well-positioned to ensure a reliable supply of AlphaMedix™ to meet the needs of patients worldwide. 🌍     A huge thank you to all our teams for their hard work and dedication in achieving this big milestone. 👏   Thank you also to Moelis & Company and McDermott Will & Emery for their financial and legal advice in finalizing this agreement.   Learn more ➡️ https://lnkd.in/eCnkxXPY ----  🚀 Accord de licence pour AlphaMedix ! 🚀    Nous sommes très heureux d'annoncer la signature d’un accord de licence exclusif avec Sanofi pour la commercialisation de notre médicament le plus avancé, AlphaMedix™, développé en partenariat avec Radiomedix, Inc. 🎉 Cet accord marque une étape décisive dans notre stratégie de développement et ouvre de nouvelles perspectives prometteuses pour #OranoMed. 🤝 En vue d’une commercialisation potentielle d'AlphaMedix™ dans les prochaines années, nous avons fait le choix stratégique de confier sa commercialisation à un acteur majeur de l'industrie pharmaceutique. Orano Med prendra en charge la production mondiale d'AlphaMedix™ via sa plateforme industrielle en pleine expansion, tandis que #Sanofi assurera la commercialisation à l'international. Grâce à nos capacités de production à grande échelle et à nos stocks de matières premières, combinés à l’envergure commerciale de Sanofi, nous disposons de tous les atouts pour garantir un approvisionnement fiable d'AlphaMedix™ et répondre aux besoins des patients à travers le monde. 🌍 Un immense merci à toutes nos équipes pour leur travail et leur engagement, qui ont permis d’atteindre ce jalon essentiel. 👏 Merci également à Moelis & Company et McDermott Will & Emery pour leurs conseils financiers et juridiques dans la conclusion de cet accord. Pour en savoir plus ➡️ https://lnkd.in/epgUNaxv #Alphatherapy #NuclearMedicine #Radiopharmaceuticals #Healthcare

Check out Michael Stumpp's presentation today at the Gordon Research Conferences and find out more about our first ²¹²Pb-labeled and DLL3-targeting RDT candidate, MP0712, for small cell lung cancer patients co-developed with Molecular Partners. #OranoMed #MolecularPartners #NuclearMedicine #MedicalInnovation #CancerResearch #Radiopharmaceuticals #Alphatherapy

🔍 Zoom sur la participation d'Orano Med à la première édition de la Journée Nationale de la #Bioproduction de #Biomédicaments, organisée par ALLIS-NA | Alliance Innovation Santé Nouvelle-Aquitaine et initiée par France BioLead.   Une semaine après son élection au Conseil d'Administration d'Allis-NA, Sophie Letournel s'est rendue en Région Nouvelle-Aquitaine pour présenter les activités d'#OranoMed et participer au showroom aux côtés des autres acteurs du secteur 🩺 Merci à Merck pour leur accueil et la visite de leur site de #Martillac ! Une journée riche en apprentissages et en échanges ! 🗣 __ 🔍Spotlight on Orano Med's participation in the first edition of the National Day of #Biomedicines #Bioproduction, organized by ALLIS-NA | Alliance Innovation Santé Nouvelle-Aquitaine and initiated by France BioLead. A week after being elected to the Board of Directors of Allis-NA, Sophie Letournel went to the Région Nouvelle-Aquitaine to present #OranoMed's activities and to participate in the showroom alongside other industry leaders 🩺 Thanks to Merck for welcoming us and for the tour of their #Martillac site. A day full of learning and networking! 🗣 #JNBB2024 #OranoMed #ALLISNA #FranceBioLead #InnovationSanté #NouvelleAquitaine

Nous sommes fiers d'annoncer qu'Orano Med sera représentée au Conseil d'Administration d' ALLIS-NA | Alliance Innovation Santé Nouvelle-Aquitaine ! 👏 Notre directrice stratégie, gouvernance et communication, Sophie Letournel, rejoindra l'équipe présidée par Philippe Lamoureux pour promouvoir l'innovation en santé en Région Nouvelle-Aquitaine. 🤝🩺   En tant que membre actif d’ALLIS-NA, Orano Med partagera sa vision de biotech dans l’écosystème de santé pour contribuer au développement de la filière, cultiver son dynamisme et favoriser les partenariats régionaux. 🚀 __ We are proud to announce that Orano Med will be represented on the Board of ALLIS-NA | Alliance Innovation Santé Nouvelle-Aquitaine! 👏 Our Strategy, Governance and Communications Director, Sophie Letournel, will join the team chaired by Philippe Lamoureux to promote innovation in healthcare in the Région Nouvelle-Aquitaine. 🤝🩺 As an active member of ALLIS-NA, Orano Med will share its biotech vision in the healthcare ecosystem to contribute to the development of the sector, foster its dynamism, and promote regional partnerships. 🚀 #OranoMed #ALLISNA #AG2024ALLIS #InnovationSanté

📣 We are pleased to announce with our partner Molecular Partners the debut of our lead Radio-DARPin therapy (RDT) candidate MP0712, targeting DLL3 for patients with small-cell lung cancer (SCLC) and other neuroendocrine tumors.    The data presented today at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto by Christian Lizak, PhD provide strong support for MP0712’s clinical development in small-cell lung cancer and other DLL3 neuroendocrine tumors. MP0712 features lead-212 as a potent therapeutic payload.    Julien Dodet, CEO of Orano Med: "We are extremely excited with the first preclinical results of the MP0712 program, which confirm the potential of the combination between Molecular Partners’ targeting technology and lead-212, an isotope perfectly suited for targeted alpha therapy. We eagerly anticipate advancing the drug’s development and initiating clinical trials to provide solutions for patients with unmet medical needs."   ➡ To find out more: https://lnkd.in/g6ka2sDm   ➡ Access the presentation here: https://lnkd.in/gqrj4gym   #SNMMI2024 #OranoMed #MolecularPartners #NuclearMedicine #MedicalInnovation #CancerResearch #RLT #Radiopharmaceuticals #Alphatherapy

🎉 ATLab inauguration by Orano Med in #Brownsburg, near Indianapolis! 🎬 A look back at the inauguration of the world's first industrial-scale pharmaceutical facility dedicated to the production of Lead-212-based radioligand therapies! This facility represents significant initial step in the company’s strategy to address challenges of the radiopharmaceutical sector in terms of production and supply of radioligand therapies. #OranoMed #MedicalInnovation #CancerResearch #NuclearMedicine #Alphatherapy

🎉 We are very proud to announce that #OranoMed, a subsidiary of the Orano Group specializing in nuclear medicine, today inaugurated the world's first industrial-scale pharmaceutical facility dedicated to the production of Lead-212-based radioligand therapies! 👏   📍 Located in #Brownsburg, near #Indianapolis, the ATLab represents a significant milestone in our industrial development and in making these promising new treatments available to cancer patients with high unmet needs in North America.   Julien Dodet: "We are convinced that lead-212 radioligand therapies will soon become an essential tool in the fight against cancer. Having obtained, together with our partner Radiomedix, Inc. Breakthrough Therapy Designation (BTD) from the FDA for our most advanced drug AlphaMedix, the inauguration of ATLab Indianapolis represents another major step forward in the development, production, and distribution of these new treatments on a large scale.”   Guillaume Dureau: "The ATLab in Indianapolis is a very important step in the development of the Orano medical activities in the U.S. Coupled with the lead-212 production capacity of our research unit in Plano, Texas – the Domestic Distribution & Purification Unit – this new industrial site will enable us to serve North American patients requiring targeted lead-212 radiotherapy treatments."   🎯 Following the groundbreaking ceremony of the ATLab Valenciennes last February to serve the European market, this new step is essential to make targeted alpha therapy for cancer patients a reality.   Learn more ➡️ https://lnkd.in/eWM4REXs Yannick Tagand Tony Denhart Ethan Pierce, MPA Vince Wong BioCrossroads Andrew Lake Wooten, Ph.D. #OranoMed #ATLabIndianapolis #MedicalInnovation #CancerResearch #FutureOfMedicine #NuclearMedicine #RLT #RadioPharmaceuticals #Alphatherapy

⏰ Tic tac tic tac ... The construction of the ATLab Indianapolis is almost complete!   Here is a little sneak peek of our first facility for the large-scale production of lead-212 radioligand therapies! And stay tuned for more exciting updates coming soon... #OranoMed #ATLabIndianapolis #Radiopharmaceuticals #Alphatherapy